MDI Health, a Tel Aviv, Israel-based provider of an AI-powered platform that automates the optimization of personalized medication treatment, raised $20M in Series A funding.
The round, which brought the total financing to $26M, was led by Intel Capital with participation from Maverick Ventures Israel and existing investors Hanaco Ventures, Welltech Ventures, Arc Impact, Basad Ventures, Fresh.Fund, Jumpspeed Ventures and former SVP of Optum Richard Montwill. As part of the fundraise, Intel Capital Investment Director Yoni Greifman will join MDI Health’s board of directors.
The company intends to use the funds to meet rising customer demand and scale its U.S. and Israeli R&D teams to drive product development.
Founded in 2019 and led by CEO Avishai Ben-Tovim, MDI Health operates an end-to-end medication treatment platform that empowers clinicians to provide comprehensive medication reviews in minutes, to help prevent adverse drug reactions, the fourth leading cause of death in the US.
The solution checks, in real time, for personalized medication related risk events, ensures patients have the exact medications they need, and enables health payers, providers and pharmacies to improve patient outcomes, medication safety, and hospitalization rates.
